Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic BMD-MSCs for ILD in CTD
NCT03929120Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Nov 2019
- Primary completion
- Jul 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic bone marrow-derived mesenchymal stem cells in interstitial lung disease (ILD), sponsored by Mayo Clinic. Primary endpoint: Adverse Events at 6 months. Started Nov 2019; status: completed.
02
Drugs
allogeneic bone marrow-derived mesenchymal stem cells
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT03929120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03929120.